LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Immunoassay Device Based on Acoustic Vortex Nanoparticle Enrichment

By LabMedica International staff writers
Posted on 08 Feb 2017
Image: A sample of 500 nanometer particles in solution. In the top image, the acoustic whirlpool device was turned off. The bottom image shows that when the device was turned on, the nanoparticles were concentrated to the point of becoming visible as a dark line down the center of the chamber (Photo courtesy of Duke University).
Image: A sample of 500 nanometer particles in solution. In the top image, the acoustic whirlpool device was turned off. The bottom image shows that when the device was turned on, the nanoparticles were concentrated to the point of becoming visible as a dark line down the center of the chamber (Photo courtesy of Duke University).
An inexpensive acoustic transducer is the key to a novel immunoassay that may eventually be combined with a smartphone camera to form a platform for the rapid detection of diagnostic proteins in blood, urine, or saliva samples.

Investigators at Duke University developed an acoustic-fluidic chip capable of generating single vortex acoustic streaming inside a glass capillary through using low-power acoustic waves (only five volts was required). The single vortex acoustic streaming that was generated, in conjunction with the acoustic radiation force, was able to enrich submicrometer- and nanometer-sized particles in a small volume. Numerical simulations were used to clarify the mechanism of the single vortex formation and were verified experimentally, demonstrating the focusing of silica and polystyrene particles ranging in diameter from 80 to 500 nanometers.

In a proof-of-principle study, the acoustic-fluidic chip was used to perform an immunoassay in which nanoparticles that captured fluorescently labeled biomarkers were concentrated in a long, thin glass vial to enhance the emitted signal.

“Diagnosis impacts about 70% of healthcare decisions,” said senior author Dr. Tony Huang, professor of mechanical engineering and materials science at Duke University. “If we can improve the quality of diagnostics while reducing its costs, then we can tremendously improve the entire healthcare system. My goal is to create a small diagnostic device about the size of a cell phone that can autonomously separate biomarkers from samples. With this vortex technology, the biomarkers could then be concentrated enough to see with a simple camera like the ones found in today’s cellular phones.”

Gold Member
Quality Control Material
iPLEX Pro Exome QC Panel
Online QC Software
Acusera 24•7
Steam Sterilizer
Hi Vac II Line
Electrolyte Analyzer
CBS-4000 (CBS-400)

Channels

Clinical Chemistry

view channel
Image: Characterization of EV separated by distinct methods (Photo courtesy of Yuanyuan Liu, Yanbin Guo et al. Engineering, doi.org/10.1016/j.eng.2025.12.009)

Liquid Biopsy Biomarkers May Improve Childhood Epilepsy Diagnosis

Childhood epilepsy remains a major neurological disorder with unmet needs for accurate, non-invasive biomarkers, as conventional tests such as electroencephalography and neuroimaging can have limited sensitivity... Read more

Molecular Diagnostics

view channel
Image: Associate Professor Arutha Kulasinghe and non-small cell lung cancer cell (Photo courtesy of The University of Queensland)

Blood-Based Proteomic Test May Predict Treatment Response in Non-Small Cell Lung Cancer

Lung cancer remains the leading cause of cancer death, with non-small cell lung cancer (NSCLC) accounting for most cases. Treatment decisions are often made without a clear indication of how a patient... Read more

Pathology

view channel
Image: Immune-related signals in routine bone marrow biopsy slides could help predict multiple myeloma outcomes and support more personalized treatment strategies (image credit: Shutterstock)

AI Tool Extracts Immune Signals from Biopsy to Inform Myeloma Therapy

Multiple myeloma is a bone marrow malignancy in which patients can respond very differently to the same treatments, making initial therapy decisions difficult. Clinicians must choose among options such... Read more
ADLM